The French regulatory agency ANSM has approved an early access program for Roche’s checkpoint inhibitor Tecentriq (atezolizumab) as a first-line treatment for patients with advanced small cell lung cancer (SCLC).
Tecentriq is being made available for this unapproved indication under a new provision introduced by the 2019 social security financing...







